HAA-09_product_DataBase

Bioactivity	HAA-09 is an orally active and potent anti-influenza agent, targeting the influenza PB2_cap binding domain. HAA-09 displays potent anti-influenza A virus activity, with an EC50 of 0.03 μM. HAA-09 shows polymerase inhibition, with an IC50 of 0.06±0.004 μM. HAA-09 blocks virus replication without causing obvious cytotoxicity[1].
Target	IC50: 0.06±0.004 μM (polymerase); EC50: 0.03 μM (influenza A virus)
Invitro	HAA-09 对奥司他韦 (oseltamivir) 敏感的 A/WSN/33 和奥司他韦耐药的 H275Y 变体表现出更强的抗病毒活性，优于奥司他韦[1]。
In Vivo	HAA-09 具有较高的血浆稳定性(t1/2≥12 h)，且无明显的 hERG 抑制作用[1]。HAA-09 (0-25 mg/kg; 口服; 每天两次) 在小鼠体内具有抗流感病毒作用[1]。 Animal Model:
Name	HAA-09
CAS	1422051-33-9
Formula	C17H18F2N6O2
Molar Mass	376.36
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Wang S, et al. Synthesis and structure-activity optimization of 7-azaindoles containing aza-β-amino acids targeting the influenza PB2 subunit. Eur J Med Chem. 2023 Mar 15;250:115185.

PeptideDB